Perspectum
Michael Rosenblatt, M.D., has held major leadership roles in academia and the biopharmaceutical industry, and currently serves as Senior Partner of Flagship Pioneering in Cambridge, MA. Dr. Rosenblatt was Chief Medical Officer (CMO) for Merck from 2009-2016. Earlier (his first of two times at Merck), he was SVP for Research at Merck Research Laboratories where he co-led the development of alendronate (FOSAMAX), now the leading therapy worldwide for osteoporosis. Additionally, he directed drug discovery efforts in molecular biology, bone biology, virology, cancer research, gastroenterology, ophthalmology, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Perspectum
Perspectum® is a medical imaging company that was founded as a spin-out from Oxford University in 2012. They discover, develop and commercialize innovative solutions for the identification and monitoring of metabolic disease and cancer, delivered through software-as-a-service (SaaS).